title: Scraping and mitomycin C to treat haze and regression after photorefractive keratectomy for myopia.
abstract: OBJECTIVE
  To evaluate the efficacy, safety, and predictability of therapeutic scraping and application of a diluted 0.02% mitomycin C solution to treat haze and regression after photorefractive keratectomy (PRK) for myopia.
  
  
  METHODS
  We performed a non-comparative, non-randomized retrospective study of 35 eyes of 30 patients who had previously undergone PRK for myopia and developed haze and regression after treatment. The range of refractive error after regression was -0.75 to -5.50 D (mean -2.92 D). Haze, ranging from grade 3 to 4 (scale: 0 to 4) caused a best spectacle-corrected visual acuity loss of 1 to 6 Snellen lines. All eyes were treated 6 to 12 months after PRK by scraping the stromal surface and application of a 0.02% mitomycin C solution for 2 minutes using a soaked merocel sponge. No laser ablation was performed. Corneal transparency, refractive error, and visual outcomes were evaluated over a 12-month follow-up period.
  
  
  RESULTS
  All eyes had significant improvement in corneal transparency. Thirty-one eyes had haze grades lower than 1, which were maintained over time. Only four eyes showed haze grades 1 to 2 and two of them needed further treatment using the same technique. At 12 months after treatment, all eyes were within +/-1.50 of original intended correction (mean 0.04 +/- 0.63 D). BSCVA improved in all eyes. No toxic effects were observed during re-epithelialization or during follow-up.
  
  
  CONCLUSIONS
  Single application of diluted mitomycin C 0.02% solution following scraping of the corneal surface was effective and safe in treating haze and regression after PRK.
authors.affiliation: Carones Ophthalmology Center, Milan, Italy. lvigo@carones.it
authors.forename: Luca
authors.initials: L
authors.lastname: Vigo
authors.forename: Elena
authors.initials: E
authors.lastname: Scandola
authors.forename: Francesco
authors.initials: F
authors.lastname: Carones
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003318:Corneal Opacity / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D019781:Corneal Topography; D006801:Humans; D054018:Lasers, Excimer; D016685:Mitomycin / Q000008:administration & dosage*; D009216:Myopia / Q000601:surgery*; D009883:Ophthalmic Solutions; D013508:Ophthalmologic Surgical Procedures; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D011183:Postoperative Complications; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin